Prelude Therapeutics stock has surged 70% in a month. Now the lending market and options positioning are confirming the shift in sentiment.
HC Wainwright's Robert Burns lit the fuse on April 27. He raised his price target from $5 to $8 — a 60% increase — while maintaining his Buy rating. That single move anchors the entire convergence now playing out across short interest, cost to borrow, and options.
The price target hike came the same day the put/call ratio hit its 52-week high of 2.41. That sounds bearish, but the options pulse flagged it as extreme bullish positioning — a Z-score of 2.47 signals the options market was pricing in a sharp sentiment shift. The PCR has since pulled back to 1.77, but remains well above the 20-day mean of 0.86.
Short sellers have been voting with their feet. SI % of free float has dropped 24% over the past month, falling from roughly 4.7% to 3.55% as of April 29. That's not a dramatic short interest level — but the speed of the exit is the story.
The cost to borrow collapsed 61% in a single week, falling to 0.63% as of April 30. A month ago it sat above 1.88%. That rapid easing tells a clear story: demand for borrows is drying up as short sellers cover.
Availability in the lending market supports this. With borrow rates near their floor, there is no squeeze dynamic here — this is an orderly exit, not a forced unwind.
The most striking data point may be institutional. OrbiMed Advisors added 2.8 million shares in a reported buy on April 21, bringing its stake to 19.3% of the company. That purchase was executed at $4.44 per share. The stock closed April 30 at $5.23 — already 18% above that entry price.
RA Capital also appears as a new holder with 5.07 million shares reported. Combined, these two specialist biotech funds now hold roughly 24% of the company.
Earnings are due May 13. PRLD has a history of large post-earnings moves — the last three prints produced 1-day swings of +23%, +22%, and +12%.
The mean analyst target sits at $6.17, implying 18% upside from current levels. Burns' new $8 target represents 53% upside.
Data summary
See the live data behind this article on ORTEX.
Open PRLD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
